269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details

臨床試験数 : 24 / 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 105

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02366260 (ClinicalTrials.gov)	February 2015	11/2/2015	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumabin Tre ...	Pyoderma Gangrenosum	Drug: Gevokizumab;Drug: Placebo	MedDerm Associates	XOMA (US) LLC	Recruiting	18 Years	N/A	Both	5	Phase 3	United States
2	NCT02326740 (ClinicalTrials.gov)	December 2014	22/12/2014	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumabin Tre ...	Pyoderma Gangrenosum	Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label	XOMA (US) LLC	NULL	Terminated	18 Years	N/A	Both	9	Phase 3	United States;Australia;Canada
3	NCT02318914 (ClinicalTrials.gov)	November 2014	8/12/2014	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: gevokizumab	XOMA (US) LLC	NULL	Terminated	18 Years	N/A	Both	15	Phase 3	United States;Australia;Canada
4	NCT02315417 (ClinicalTrials.gov)	November 2014	5/12/2014	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumabin Tre ...	Pyoderma Gangrenosum	Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label	XOMA (US) LLC	NULL	Terminated	18 Years	N/A	Both	16	Phase 3	United States
5	NCT01882504 (ClinicalTrials.gov)	May 2013	17/6/2013	Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum	An Open-label, Proof of Concept Study of Gevokizumabin the Treatment of the Acute, Inflammatory Phas ...	Pyoderma Gangrenosum	Drug: gevokizumab	XOMA (US) LLC	NULL	Completed	18 Years	N/A	Both	8	Phase 2	United States

First Previous1Next Last